Global Meningococcal Vaccine Market Set to Surge with Projected Growth to USD 9014 million by 2034

The global meningococcal vaccine market is on an impressive growth trajectory, driven by rising incidences of the disease worldwide. As of 2024, the market is valued at approximately USD 3950.2 million and is expected to soar to USD 9014 million by 2034, reflecting a remarkable Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period from 2024 to 2034.

The prevalence of meningitis remains a significant global health concern. In 2019 alone, approximately 2.51 million cases of meningitis were reported worldwide, with 1.28 million of those cases affecting children under five years old. The severity and fatality of the disease have spurred heightened awareness and a concerted push for vaccination, especially in countries with established healthcare systems such as the United States, the United Kingdom, India, and China.

A key factor driving market growth is the increasing awareness among both healthcare professionals and the general population about the life-threatening nature of meningococcal disease. Governments worldwide have also implemented targeted immunization programs for infants, adolescents, and young adults, which is further bolstering demand for vaccines. These efforts aim to curb the incidence of meningococcal disease and protect vulnerable populations.

In addition, advancements in vaccine development are contributing significantly to the market’s expansion. With technological innovations, vaccine manufacturers are producing more effective and convenient vaccines. These vaccines offer broader protection against multiple strains of meningococcal bacteria and require fewer doses, making them attractive to both healthcare providers and patients.

Government initiatives and expanding vaccination recommendations in both developed and developing countries are creating an optimistic outlook for the meningococcal vaccine market. With a growing focus on preventive healthcare, the market is poised for robust growth over the next decade.

As global health organizations and governments intensify their commitment to combating meningococcal disease, the future of the meningococcal vaccine market looks promising, with increased access to vaccines and a broader scope of immunization programs set to drive sustained growth.

Key Takeaways:

• Market Growth: The meningococcal vaccine market has witnessed substantial growth, with a projected increase from USD 3950.2 million in 2024 to USD 9014 million by 2034, reflecting a CAGR of 8.6% during this period.
• United Kingdom’s Influence: The UK is expected to exhibit a CAGR of 9.8% by 2034. Its strong national immunization program, incorporating meningococcal vaccines as part of routine childhood and adolescent vaccinations, is driving significant demand and industry growth.
• United States Regulations: The US market is set to grow at a CAGR of 9.4% through 2034, with government mandates requiring meningococcal vaccination for school and college entry. These regulations ensure high vaccination coverage and fuel vaccine adoption.
• China’s Expansion: China is projected to experience a 9.5% CAGR in the meningococcal vaccine market from 2024 to 2034. The government’s post-pandemic investment in healthcare infrastructure and public well-being is driving substantial demand for meningococcal vaccines across the country.

Surge in Market Needs: Discover Comprehensive Analysis and Insights in Our Detailed Report!

Competitive Landscape:

The global meningococcal vaccine market is largely shaped by advancements in vaccine formulations, with companies focusing on the efficiency, cost-effectiveness, and safety of their products to attract consumers. Market players are also forging partnerships with governments and international organizations to broaden their market presence and ensure that vaccines are accessible to a larger population.

Leading companies in the market include GlaxoSmithKline plc, Pfizer Inc., Sanofi Pasteur, Merck & Co., Inc., and Novartis AG.

Recent Industry Developments:

In April 2024, Nigeria made a landmark achievement by launching the world’s first 5-in-1 meningitis vaccine, Men5CV. Endorsed by the World Health Organization (WHO), this vaccine targets the deadly disease, with a vaccination campaign initially aimed at over one million individuals aged 1-29.

In November 2023, GlobalData highlighted major shifts in the meningococcal vaccine landscape following the introduction of Pfizer’s Penbraya. The CDC’s Advisory Committee on Immunization Practices recommended the simultaneous administration of Penbraya, along with MenACWY and MenB vaccines, for eligible individuals aged 10 years and older.

Leading Meningococcal Vaccines Brands:

• CSL Limited
• Johnson & Johnson
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Biological E Limited
• Chongqing Zhifei Biological Products Co., Ltd.
• Beijing Tiantan Biological Products Co., Ltd.
• Hualan Biological Engineering Inc.
• Walvax Biotechnology Co., Ltd.
• Bio-Manguinhos (Fiocruz)
• Hangzhou Jinjiang Group Co., Ltd.
• Shenzhen Kangtai Biological Products Co., Ltd.
• Biomed Pvt. Ltd.
• GlaxoSmithKline Biologicals SA

Key Segments of Market Report:

On the basis of product type:

The sector is bifurcated into polysaccharides and conjugates.

Based on the age group:

The industry is segmented into infants, children, adolescents, young adults, and adults.

On account of end users:

The sector is segmented into, pharmacies, community, clinics, public health agencies, and others.

As per region:

The industry is divided into North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube